Addition of immune therapy ‘shows promise’ in gastric cancer
But two trials of first-line therapy have differing overall survival outcomes.
Tag: Conference coverage
Could PD-L1 positive cell density be a prognostic biomarker?
The hunt is on for ways to predict response to immune checkpoint inhibitors in NSCLC.
Adjuvant therapy ‘cuts risk of brain metastases’ in NSCLC
Osimertinib is a practice-changing treatment for certain patients with completely resected EGFR-mutated disease, researcher says.
Drug reduces invasive disease toll in high-risk early breast cancer: study
Interim results from the open-label trial suggest abemaciclib has benefit, researchers say.
Postoperative radiotherapy ‘not advisable’ in advanced NSCLC
Trial findings clarify lack of benefit and increased cardiopulmonary toxicity.Â
Combo therapy ‘beneficial’ in metastatic prostate cancer
Trial results show improved clinical outcome in a subset of men with castration-resistant disease, researchers say.
Palbociclib improves survival in late endometrial cancer: study
Results from a phase 2 trial with letrozole in oestrogen receptor-positive patients.
New combo therapy ‘effective first line in advanced renal cancer’
The first results of the CheckMate 9ER trial show a good response rate and improved survival, researchers say.
Neoadjuvant immune checkpoint therapy trialled for NSCLC
Two different phase 2 trials suggest most patients can go on to have full resection.
Mystery over two triple-negative breast cancer trial results
Does the type of paclitaxel make a difference to outcomes?
